Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates [Yahoo! Finance]
Praxis Precision Medicines, Inc. (PRAX)
Company Research
Source: Yahoo! Finance
Recap of the Week's Most Important Stories Setback for Regeneron Regeneron Pharmaceuticals, Inc . REGN suffered a setback as the FDA issued Complete Response Letters (CRLs) for its biologics license application (BLA) for odronextamab. The BLA is seeking the approval of the candidate in relapsed/refractory (R/R) follicular lymphoma (FL) and in R/R diffuse large B-cell lymphoma (DLBCL), each after two or more lines of systemic therapy. Regeneron stated that the sole issue with approvability is related to the enrollment status of the confirmatory trials. The CRLs — one for R/R FL and one for R/R DLBCL — did not identify any approvability issues with the clinical efficacy or safety, trial design, labeling or manufacturing of the candidate. REGN has been actively enrolling patients in multiple phase III trials for odronextamab as part of the OLYMPIA program. The program is expected to change the treatment paradigm of several B-cell non-Hodgkin lymphoma subtypes, including in earlier l
Show less
Read more
Impact Snapshot
Event Time:
PRAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRAX alerts
High impacting Praxis Precision Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
PRAX
News
- Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $105.00 price target on the stock.MarketBeat
- Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual MeetingGlobeNewswire
- Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why [Yahoo! Finance]Yahoo! Finance
- Praxis Precision Medicines to Participate in Upcoming April Conferences [Yahoo! Finance]Yahoo! Finance
PRAX
Earnings
- 3/5/24 - Beat
PRAX
Sec Filings
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- 3/29/24 - Form 8-K
- PRAX's page on the SEC website